Literature DB >> 14512317

Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13.

John E Pimanda1, Akiko Maekawa, Troels Wind, Julian Paxton, Colin N Chesterman, Philip J Hogg.   

Abstract

Severe deficiency of the von Willebrand Factor (VWF)-cleaving proteinase, ADAMTS13, is associated with the development of thrombotic thrombocytopenic purpura (TTP). Several mutations spread across the ADAMTS13 gene have been identified in association with a deficiency of VWF-cleaving proteinase activity in patients with congenital TTP. The spread of these dysfunctional mutations and the domain structure of ADAMTS13 are suggestive of a complex interaction between the enzyme and its substrate. We have studied a patient with congenital TTP who is a compound heterozygote for the Thr196Ile mutation in the metalloproteinase domain and a frameshift mutation (4143-4144insA) in the second CUB domain that results in loss of the last 49 amino acids of the protein. The VWF-cleaving proteinase activity of the truncated enzyme was comparable to that of the wild-type enzyme but its secretion from transfected COS-7 cells was about 14% of the wild type.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14512317     DOI: 10.1182/blood-2003-04-1346

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor.

Authors:  Jihui Ai; Paula Smith; Shuwei Wang; Ping Zhang; X Long Zheng
Journal:  J Biol Chem       Date:  2005-06-23       Impact factor: 5.157

Review 2.  ADAMTS13 and microvascular thrombosis.

Authors:  Han-Mou Tsai
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-11

3.  Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy?

Authors:  Wenhua Zhou; Lingli Dong; David Ginsburg; Eric E Bouhassira; Han-Mou Tsai
Journal:  J Biol Chem       Date:  2005-10-03       Impact factor: 5.157

4.  Why Do We Need ADAMTS13?

Authors:  Han-Mou Tsai
Journal:  Nihon Kessen Shiketsu Gakkai shi       Date:  2005

5.  Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions.

Authors:  Zhenyin Tao; Yuandong Peng; Leticia Nolasco; Santiago Cal; Carlos Lopez-Otin; Renhao Li; Joel L Moake; José A López; Jing-Fei Dong
Journal:  Blood       Date:  2005-09-01       Impact factor: 22.113

6.  Cyclosporin A impairs the secretion and activity of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat).

Authors:  Klilah Hershko; Vijaya L Simhadri; Adam Blaisdell; Ryan C Hunt; Jordan Newell; Sandra C Tseng; Alon Y Hershko; Jae Won Choi; Zuben E Sauna; Andrew Wu; Richard J Bram; Anton A Komar; Chava Kimchi-Sarfaty
Journal:  J Biol Chem       Date:  2012-11-09       Impact factor: 5.157

Review 7.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

8.  N-Glycans of ADAMTS13 modulate its secretion and von Willebrand factor cleaving activity.

Authors:  Wenhua Zhou; Han-Mou Tsai
Journal:  Blood       Date:  2008-11-03       Impact factor: 22.113

Review 9.  The kidney in thrombotic thrombocytopenic purpura.

Authors:  H-M Tsai
Journal:  Minerva Med       Date:  2007-12       Impact factor: 4.806

Review 10.  Pathogenesis of thrombotic microangiopathies.

Authors:  X Long Zheng; J Evan Sadler
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.